Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers
Journal of Neural Transmission · 2026-10 · 133 (10) · 2979-2986
DOI: 10.1007/s00702-026-03233-w ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Neural Transmission, online erschienen am 21.07.2026. Verfasst von Achim Wach und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1A Consulting, Dr Wach & Wach GbR, Weil am Rhein, Germany. Hauptthemen laut MEDLINE: Carbidopa, Levodopa, Antiparkinson Agents. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zambon Biotech SA.
Abstract (Originalsprache)
Optimizing oral levodopa delivery by prolonging duration of effect remains a key challenge in managing OFF periods in Parkinson’s disease. IPX203 is an oral modified-release formulation combining immediate-release (IR) and extended-release (ER) levodopa with IR carbidopa, designed to provide rapid onset and sustained exposure. We characterized pharmacokinetics of levodopa and carbidopa following IPX203 compared with IR and controlled-release (CR) levodopa/carbidopa using population pharmacokinetic modeling from a Phase 1 study in healthy volunteers. Plasma concentration–time data were analyzed using nonlinear mixed-effects modeling. Formulation-specific absorption models, including a dual-depot model for IPX203, were combined with a shared systemic disposition model. The models adequately described observed levodopa and carbidopa concentrations across formulations. Marked formulation-dependent differences in levodopa exposure were driven by absorption. IR-levodopa/carbidopa produced rapid absorption with peak concentrations followed by a steep decline, consistent with elimination-rate–limited pharmacokinetics. CR-levodopa/carbidopa showed delayed absorption with lower peak concentrations and limited time within the expected therapeutic range (750–1000 ng/mL). In contrast, IPX203 exhibited biphasic absorption, with an initial IR-driven peak and sustained concentrations from the ER component, consistent with rate-limited absorption and prolonged intestinal residence. This resulted in reduced peak–trough fluctuation and longer duration within therapeutic range. Carbidopa profiles were qualitatively similar, with higher absolute exposure for IPX203. Model-based simulations of commonly used dosing regimens suggested that IPX203 administered every 6 h achieved the most stable levodopa concentrations. These findings indicate that IPX203 provides a distinct exposure profile characterized by rapid onset and sustained levodopa exposure driven by controlled absorption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1A Consulting, Dr Wach & Wach GbR, Weil am Rhein, Germany.
- Zambon Biotech SA, Medical Affairs, Cadempino, Switzerland.
- Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, SE1 1UL, UK. peter.jenner@kcl.ac.uk.
Förderung
- Zambon Biotech SA
Zitieren
APA
Wach, A., Kopra, J., Marjanovic, I., Knecht, M., & Jenner, P. (2026). Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers. Journal of Neural Transmission, 133(10), 2979-2986. https://doi.org/10.1007/s00702-026-03233-w
Vancouver
Wach A, Kopra J, Marjanovic I, Knecht M, Jenner P. Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers. Journal of Neural Transmission. 2026;133(10):2979-2986. doi:10.1007/s00702-026-03233-w
BibTeX
@article{Wach2026,
author = {Wach, Achim and Kopra, Jaakko and Marjanovic, Ivan and Knecht, Mathias and Jenner, Peter},
title = {Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers},
journal = {Journal of Neural Transmission},
year = {2026},
volume = {133},
number = {10},
pages = {2979--2986},
doi = {10.1007/s00702-026-03233-w}
}
EUVIMED